- Continue to consolidates GENFITs position as a manager acute-on-chronic liver failure (ACLF)
- Sexpand significantlys GENFIT’s pipeline with VS-01-ACLF, a Phase 2 done program related to best in class Wash Liposome Technology, VS-01-UCD, a paediatrics program focused on urea cycle disorders (UCD), and VS-02-HE, a early time program focused hepatic encephalopathy (HE)
- Combines Versantis‘ expertise With GENFIT’s expertise while conducting complex development programs in liver diseasesto strengthen and Accelerate research and development
- Deal terms include a payment from CHF40 milliona total of CHF 65 million possible additional payments depending on success clinical and rregulatory milestonesand one-third of the net proceeds of potential Selling a Priority Review Voucher if issued by the FDA
- GENFIT will host a live conference call in English and French today, September 19, at 8:00 am ET / 1:00 pm GMT / 2:00 pm CET
Lille, France; Cambridge, MA; September 19, 2022 – GENFIT (Nasdaq and Euronext: GNFT)a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver disease, announced today that it has entered into an exclusivity agreement to acquire all of the share capital and voting rights of Versantis, a private hospital based in Switzerland , to acquire a biotechnology company focused on addressing the growing unmet medical need in liver disease.
The acquisition of Versantis fits perfectly into GENFIT’s strategic vision to become a global leader in ACLF (acute chronic liver failure) and is another key milestone in the execution of GENFIT’s strategic plan. With this acquisition, GENFIT solidifies its position with ACLF through the integration of a clinically advanced asset that provides a solid scientific foundation supported by encouraging Phase 1b and preclinical data. GENFIT will also continue to expand its pipeline in other liver diseases characterized by high unmet medical needs with additional products…
